Kornimate/medical-research-clean huggingface dataset:
the role of pentraxin 3 and cathepsin b levels in preeclamptic pregnancy

Conditions: Pre-Eclampsia; Cathepsin B Level; Pentraxin 3 Level

Summary: in this study, the investigator aim was to compare cathepsin b and pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of cathepsin b and pentraxin 3 levels alone or together and contribute to the literature in this area.

this prospective case-control study was conducted between 1 january 2022 and 31 december 2022 at bursa yuksek ihtisas training and research hospital. the study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. this study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; group1: patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , group 2: healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . as soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the cathepsin b and pentraxin 3 kit in amounts suitable for the study. the samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. after all samples were collected, cathepsin b and pentraxin 3 values were measured by elisa method.

Eligibility criteria:
inclusion criteria: * singleton pregnancy * pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation * healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study. exclusion criteria: * multiple pregnancies * pregnant women who gave birth below 24 weeks of gestation * pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension) * pregnant women with chromosomal or congenital anomalies in the fetus * women with a known infective or autoimmune disease before pregnancy

Keywords: second trimester preeclampsia pentraxin 3 cathepsin b
the difference in cerebral oxygenation between propofol and sevoflurane

Conditions: Cerebral Hypoxia; Postoperative Cognitive Dysfunction

Summary: the purpose of this study is to investigate whether propofol and sevoflurane have difference effect on cerebral oxygenation .

the purpose of this study:(1) to investigate the incidence of preoperative cerebral oxygenation abnormity (sjvo2 \<55%) and its relationship with intraoperative cerebral desaturation and pocd. (2) to investigate the change of intraoperative cerebral oxygen supply and demand balance and the incidence of cerebral desaturation in patients with abnormal preoperative cerebral oxygenation during sevoflurane anesthesia. (3)to investigate the incidence of early pocd in patients with abnormal preoperative cerebral oxygenation during sevoflurane and propofol anesthesia.

Eligibility criteria:
inclusion criteria: * scheduled to take major surgery under general anesthesia over 18 years old classified as asa class three or less exclusion criteria: * have a diagnosis of cerebrovascular disorder

Keywords: jugular bulb oxygen saturation postoperative cognitive dysfunction propofol sevoflurane
multiplex analysis of circulating tumor dna

Conditions: Carcinoma; Non-small-cell Lung Cancer; Lung Neoplasm

Summary: lung cancer is the leading cause of cancer-related death in china. this study will explore the applications of multiplex analysis of circulating tumor dna biomarkers for diagnosis and surveillance of lung cancer patients

non-small cell lung cancer (nsclc) constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide.early diagnosis and monitoring tumor recurrence after surgery are still far from satisfying. circulating tumor dna(ctdna) detection has been proved to be feasible in early stage nsclc in previous studies.both genomic mutation and methylation a promising biomarker.therefore,this study will perform multiplex detection of ctdna,analysing mutations, methylation and other biomarkers,focusing on the early diagnosis and postoperative surveillance for nsclc patients.

Eligibility criteria:
inclusion criteria: 1. sign informed consent and consent to participate in this study; 2. found small nodules in pulmonary by ct and prepare for surgery; exclusion criteria: 1. malignant tumor history within the past 5 years; 2. receiving chemotherapy, radiotherapy or targeted therapy before surgery; 3. no matching tissue or blood samplesunqualified blood samples 4. lesion is pure ground glass opacity.

Keywords: circulating tumor dna early diagnosis surveillance methylation somatic mutation
initial resuscitation with albumin in hemorrhagic shock to reduce positive fluid balance

Conditions: Bleeding; Massive Hemorrhage; Massive Transfusion Protocol

Summary: this study is designed to evaluate the effect of early albumin transfusion within massive transfusion protocol on fluid balance and reduced requirement of transfusion.

eligible patients who require massive transfusion will be randomized in a single-blind manner (participant) in a 1:1 ratio to conventional massive transfusion pro. tocol group (c-mtp) or albumin massive transfusion protocol group (a-mtp). when mtp is initiated according to the result of randomization, all patients(or a legal guardian) are informed about the study and potential risks and benefits. study will be continued only in patients who give informed consent.

Eligibility criteria:
inclusion criteria: * adult patients (19 or older) * admitted or planned to admit surgical intensive care unit * patients with decreased hemoglobin level more than 20% from baseline within 12 hours, or * patients who are suspected bleeding and hemodynamically unstable requiring more than 0.05mcg/kg/min of norepinephrine infusion to maintain mean blood pressure higher than 65mmhg exclusion criteria: * contraindicated to albumin product * patients with risk factors of increased circulatory volume (heart failure, pulmonary edema, end-stage renal disease with oliguria) * patients with hemolytic anemia * history of anaphylactic reaction to blood product

Keywords: massive transfusion protocol massive transfusion albumin
research on neurological prognosis of patients undergoing heart valve surgery

Conditions: Heart Valve Diseases; Image

Summary: the purpose of this study is to clarify the changes of neurocognitive function of patients undergoing cardiac valve disease before and after surgical treatment under cardiopulmonary bypass operation, and to predict the neurological prognosis of such patients through combined imaging technology, so as to improve and avoid the occurrence of postoperative neurological dysfunction in such patients.

this study focuses on brain protection in patients with heart disease. the preoperative brain imaging and consciousness and cognition evaluation results, intraoperative brain monitoring indicators, adverse events of neurological function, brain imaging and consciousness and cognition evaluation results during the postoperative and follow-up periods were recorded. at the same time, serum markers related to perioperative neurological function were obtained to explore the relevant factors affecting neurocognitive function during the perioperative period. the research objectives to investigate the perioperative changes of neurocognitive function in patients undergoing heart valve surgery under cardiopulmonary bypass and the related factors affecting the prognosis of neurocognitive function.

Eligibility criteria:
inclusion criteria: * aged 45-80 years old. * accept heart biological valve replacement or heart valvuloplasty. * more than 6 years of education. * at baseline, the score of mini-mental state examination (mmse) scale is more than 23 points exclusion criteria: * patients who failed to obtain informed consent. * preoperative diagnosis of stroke, epilepsy, history of craniocerebral surgery, cerebrovascular disease, psychosis and rescue patients with cardiopulmonary resuscitation before operation. * alcoholism, illiteracy and left-handed. * there was severe organ hypoperfusion or organ dysfunction before operation, including: preoperative myocardial infarction \< 90 days, renal failure or dialysis, severe liver injury, digestive tract ischemia, spinal cord ischemia and iliac artery occlusion. * there are contraindications to magnetic resonance examination, such as claustrophobia and metal implants in the body. * pregnant or lactating women. * participating in other clinical studies will affect the main indicators of this study.

Keywords: heart valve diseases cardiopulmonary bypass mri imaging neuropsychological assessment
could the therapy with inositol affect the cardiovascular risk in pcos women? results of a randomized clinical trial

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is associated with an increased cardiovascular risk. the aim of the study was to evaluate long-term effects of inositol on some cardiovascular risk factors in pcos patients.


Eligibility criteria:
inclusion criteria: * polycystic ovary syndrome * age \>18 and \<35 exclusion criteria: * chronic or acute inflammatory disease, cancer, autoimmune disease, treatment during the last 6 months prior to our evaluation, dm2, hypertension, major surgery in the last 3 months or other hormonal dysfunctions (hypothalamic, pituitary, thyroidal, or adrenal causes).

Keywords: polycystic ovary syndrome cardiovascular risk metabolic syndrome
dexamethasone for the prevention of post-operative nausea and vomiting in patients undergoing cesarean sections

Conditions: Postoperative Nausea and Vomiting

Summary: patients who present for scheduled (non-emergent) cesarean section will be given either intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal anesthetic. the investigators will then compare the incidence of nausea and vomiting and the use of rescue anti-nausea medications in both groups. our hypothesis is that patients receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section will have a significantly lower incidence and severity of ponv at 0, 1, 3, 6, and 24 hours following surgery.

women having cesarean sections commonly experience post-operative nausea and vomiting (ponv). this can be partly attributed to the long acting morphine (duramorph) given in the anesthetic (either through the epidural or in the spinal anesthetic). intravenous dexamethasone is a widely used steroid medication with a well-established safety profile which is the standard of care for the prevention of ponv for general anesthesia in both adult and pediatric surgical patients. many studies have shown that when intravenous dexamethasone is administered before duramorph in the epidural, the incidence of nausea and vomiting following cesarean section is significantly reduced. however, when patients receive intravenous dexamethasone after duramorph in a spinal anesthetic, it does not reduce the incidence of nausea and vomiting. there are not any published studies where dexamethasone was administered before a spinal anesthetic. the investigators believe that if dexamethasone is given intravenously before duramorph in a spinal anesthetic it may reduce the incidence of nausea and vomiting. patients who present for scheduled (non-emergent) cesarean section will be given either intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal anesthetic. the investigators will then compare the incidence of nausea and vomiting and the use of rescue anti-nausea medications in both groups. our hypothesis is that patients receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section will have a significantly lower incidence and severity of ponv at 0, 1, 3, 6, and 24 hours following surgery.

Eligibility criteria:
inclusion criteria: * women aged 18-46 presenting for scheduled primary or repeat cesarean sections and have consented to study exclusion criteria: * allergy to dexamethasone or morphine * history of gastrointestinal disease * history of severe nausea during pregnancy (hyperemesis gravidarum) * use of anti-emetic in the past 24 hours * history of gestational diabetes or diabetes mellitus * history of hypertension prior to or during pregnancy * presence of non-viable fetus

Keywords: cesarean section nausea vomiting dexamethasone postoperative nausea and vomiting antiemetics
corneal collagen cross-linking for ectasia (cxl)

Conditions: Ectasia

Summary: prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (cxl) using riboflavin and uva light in eyes with ectasia after refractive surgery.

subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. corneal collagen cross-linking is performed as a single treatment. subjects are followed for 12 months after the procedure to evaluate the long term effects of corneal collagen cross-linking.

Eligibility criteria:
inclusion criteria: * diagnosis of ectasia after refractive surgery * documented ectasia on pentacam or topography map * bscva worse than 20/20 * must complete all study visits exclusion criteria: * history of delayed wound healing * history of corneal melt or corneal dystrophy

Keywords: ectasia cross-linking crosslinking cornea riboflavin uva
balance targeted exercises for individuals with ms

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to examine the effects of a postural adjustment, targeted training program on balance ability and postural responses anticipatory postural adjustments (apa) and compensatory postural adjustments (cpa) in individuals with ms

all participants participated in individual training program aimed at improving balance ability and postural adjustments. the training program and individual activities were based on previously published programs and motor learning principles, and consists of 18, 1-hour training sessions over six weeks (3 sessions/week). training occurred in person 2 days a week (in person training) and at home (home exercise program) 1 day a week, for a total of 3 sessions per week. the duration of training sessions were 60 minutes per session for a total of 1,140 minutes of training. the exercise room temperature was centrally regulated (23.3 degrees c).

Eligibility criteria:
inclusion criteria: 1. must be18 to 70 years of age. 2. medical diagnosis of ms confirmed by a neurologist. 3. ability to stand independently without any aid for at least 3 minutes. 4. a patients determined disease steps (pdds) score of 5 or lower. 5. normal or corrected-to-normal vision. 6. english or spanish speaking. exclusion criteria: 1. ms-related exacerbation or medication change in the past two months. 2. presence of concurrent neurological or orthopedic disorders. 3. unable to perform the experimental tasks.
efficacy, safety and tolerability study of shape in ia, ib or iia cutaneous t-cell lymphoma

Conditions: Cutaneous T-Cell Lymphoma (CTCL)

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of shape administered topically to skin lesions in patients with early-stage cutaneous t-cell lymphoma (ctcl).

this is a phase 2, multicenter, open-label, randomized study to evaluate the efficacy and safety of shape gelled solution applied topically daily or twice daily for 26 consecutive weeks to specified skin lesions in patients with stage ia, ib or iia ctcl. patients responding to treatment will be allowed to continue on study for a maximum of 52 weeks.

Eligibility criteria:
inclusion criteria: * histological confirmation of ctcl; a documented verifiable biopsy report is required * documented clinical stage ia, ib or iia ctcl * skin lesion involvement of at least 2% of bsa accessible for topical application of study drug * ecog performance status of 0-2 exclusion criteria: * ctcl with histologic evidence of folliculotropic variant or large cell transformed ctcl * palpable lymph node ≥1.5 cm in diameter (unless the lymph node has been biopsied and designated as stage ia-iia disease) * co-existent second malignancy or history of prior solid organ malignancy within previous 5 years (excluding basal or squamous cell carcinoma, in situ carcinoma of the cervix (cin3), papillary or follicular thyroid cancer or prostate cancer that has been treated curatively * any prior history of hematologic malignancy (other than ctcl) within past 5 years * ctcl disease that is known to be refractory to systemic histone deacetylase inhibitors * prior or concurrent central nervous system (cns) metastases * history of or current major gastrointestinal, pulmonary, cardiovascular, genitourinary or hematologic disease, cns disorders, infectious disease or coagulation disorders as determined by the investigator * evidence of active hepatitis b or c or hiv * circulating atypical cells of clinical significance

Keywords: ctcl cutaneous t-cell lymphoma early-stage shape shp-141 topical histone deacetylase inhibitor cails mswat mycosis fungoides
effects of aerobic and isokinetic exercise in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the investigators aimed in this study to measure the muscular strength, cardiovascular system and quality of life effects of rehabilitation with aerobic and isokinetic exercise program in ms patients.

a total of 40 patients enrolled in the study from outpatient clinics were included. two groups were formed, namely 'aerobic exercise' and 'isokinetic exercise' groups. using modified bruce protocol, effort capacities were measured with humac norm cybex dynamometer, 6 min. walking distance and msqol-54 scale were used to assess the quality of life. the aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise. patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study. the exercise program was applied for 8 weeks with 3 repetitions per week. assessment of exercise capacity (effort capacity) was performed by applying the norav trackmaster tmx 425 treadmill exercise device by applying modified bruce protocol. patients' total exercise times were expressed in seconds. indirect maximum amount of oxygen volume (vo2 max) values were calculated using heart rate obtained with submaximal treadmill exercise.all the cases participating in the study were compared in terms of the pre-treatment msqol-54 scale and the msqol-54 scale subscale.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of multipl sclerosis * 18-65 years old adults * patients signed informed consent forms exclusion criteria: * non-ms musculoskeletal system diseases * congenital anomalies, limb amputations * accompanying neurological diseases (parkinson, alzheimer, polyneuropathy etc.) * vestibular system diseases * chronic diseases (diabetes mellitus, chronic obstructive pulmonary disease, hypertension, hyperlipidemia, severe cardiac disease, malignancy) * pregnancy.

Keywords: multiple sclerosis aerobic isokinetic exercise
simulated clinical use testing to evaluate sharps injury prevention features of htl-strefa's safety lancets (test c)

Conditions: Accident Injury

Summary: a simulated clinical use testing to evaluate the medlance plus and mylance sharps injury prevention feature in accordance with the fda's guidance on medical devices with sharps injury prevention features.

this study aims to evaluate the safety of the use of the following safety lancets: medlance plus and mylance in the prevention of needle-stick injury (nsi) and to evaluate the user's opinion with regard to the handling characteristics of the medical devices. the simulated use clinical study involves healthcare professionals (hcps) who routinely use safety lancets to collect blood samples.

Eligibility criteria:
inclusion criteria: * evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts) * evaluators will be united states (us) residents * evaluators can read, write, and speak english * evaluators are at least 18 years old * evaluators are able to understand and provide signed consent for the study * evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires. * evaluators have no concerns about the ability to perform the simulated skin pricking. exclusion criteria: * evaluators who do not routinely use safety lancets to collect capillary blood samples, * evaluators who cannot read, write, and speak english, * evaluators or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or * evaluators who have participated in a product evaluation or marketing study involving safety lancets within the last six months

Keywords: safety lancet capillary blood sampling accidental needle-stick injury
surgical vs transcatheter aortic valve replacement in young patients

Conditions: Symptomatic Severe Aortic Stenosis

Summary: the study objective is to demonstrate that the clinical outcomes of the myval balloon-expandable thv series are non-inferior to those of savr in patients with symptomatic severe aortic stenosis aged 65 to 75 years.

prospective, randomized, multinational, multicenter, open label, trial of 1180 patients treated with surgical bioprosthetic aortic valve replacement (savr) or transcatheter aortic valve replacement (tavr).

Eligibility criteria:
inclusion criteria: participant will be included if all the following criteria are met: 1. patients aged ≥65 and ≤75 2. symptomatic severe aortic stenosis (mean gradient≥40mmhg, and or peak velocity\>4m/sec). 3. patients with symptomatic heart disease due to severe native calcific aortic stenosis, as judged by a multidisciplinary heart team (including a cardiac surgeon), for whom savr or transfemoral tavr is deemed feasible and approved by the local heart team.signed informed consent for participation in the clinical investigation exclusion criteria: participant will not be included if any one of the following conditions exists: 1. unable to understand and follow clinical investigation-related instructions or unable to comply with the clinical investigation protocol 2. life expectancy less than 1 year 3. known hypersensitivity or allergy to aspirin, clopidogrel or any device frame components. 4. under judicial protection, tutorship, or curatorship 5. participation in another trial before the primary endpoint
duloxetine for the treatment of generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: this is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder


Eligibility criteria:
inclusion criteria: * psychiatric diagnosis of generalized anxiety disorder (gad) * outpatients * meet diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) diagnosis for gad * clinical global impression (cgi) of severity score of at least moderate * sheehan disability scale (sds) global functioning impairment score \>= 12 exclusion criteria: * pregnancy or breast feeding * serious medical illness * other primary psychiatric diagnoses, such as major depressive disorder or substance abuse disorder within the past 6 months * panic disorder, post-traumatic stress disorder (ptsd), or eating disorder in the last year * lifetime history of bipolar or psychosis * any unstable serious medical condition for which duloxetine would not be allowed * any use of medications that are not allowed

Keywords: anxiety